$LONA News

LeonaBio to Participate in Cantor Global Healthcare Conference 2026

LeonaBio Enrolls 500th Subject In Phase 3 ELAINE-3 Trial For Lasofoxifene With Abemaciclib

Mizuho Maintains Outperform on LeonaBio, Lowers Price Target to $15

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

Citizens Maintains Market Outperform on LeonaBio, Lowers Price Target to $17

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

LeonaBio Q2 EPS $(0.80) Beats $(1.36) Estimate

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer

LeonaBio’s Lead Product Candidate, Lasofoxifene, To Be Featured In Multiple Presentations At Dava Oncology’s 4th Summit On Breast Cancer

Citizens Upgrades LeonaBio to Market Outperform, Announces $18 Price Target

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

Piper Sandler Initiates Coverage On LeonaBio with Overweight Rating, Announces Price Target of $20

LeonaBio (NASDAQ:LONA) Beats Q1 Loss Estimates as Phase 3 Breast Cancer Trial Enrollment Expands

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

LeonaBio Q1 EPS $(1.73) Beats $(2.50) Estimate

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.

LeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene Transcript

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data